These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 32145969)

  • 1. Remission in psoriatic arthritis: Definition and predictors.
    Alharbi S; Ye JY; Lee KA; Chandran V; Cook RJ; Gladman DD
    Semin Arthritis Rheum; 2020 Dec; 50(6):1494-1499. PubMed ID: 32145969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual Disease Activity and Associated Factors in Psoriatic Arthritis.
    Lubrano E; Scriffignano S; Perrotta FM
    J Rheumatol; 2020 Oct; 47(10):1490-1495. PubMed ID: 31676704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
    Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
    J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
    Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
    Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis.
    Sheane BJ; Thavaneswaran A; Gladman DD; Chandran V
    J Rheumatol; 2016 Sep; 43(9):1718-23. PubMed ID: 27422895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis.
    Eder L; Thavaneswaran A; Chandran V; Cook RJ; Gladman DD
    Ann Rheum Dis; 2015 May; 74(5):813-7. PubMed ID: 24431392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of Achieving Remission among Patients with Psoriatic Arthritis Initiating a Tumor Necrosis Factor Inhibitor.
    Ogdie A; Palmer JL; Greenberg J; Curtis JR; Harrold LR; Solomon DH; Kavanaugh A; Kremer JM; Mease PJ
    J Rheumatol; 2019 May; 46(5):475-482. PubMed ID: 30647182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-related differences in disease activity and clinical features in patients with peripheral psoriatic arthritis: A multi-center study.
    Duruöz MT; Gezer HH; Nas K; Kılıç E; Sargın B; Kasman SA; Alkan H; Şahin N; Cengiz G; Cüzdan N; Gezer İA; Keskin D; Mülkoğlu C; Reşorlu H; Ataman Ş; Bal A; Küçükakkaş O; Yurdakul OV; Melikoğlu MA; Baykul M; Ayhan FF; Bodur H; Çalış M; Çapkın E; Devrimsel G; Gök K; Hizmetli S; Kamanlı A; Keskin Y; Ecesoy H; Kutluk Ö; Şen N; Şendur ÖF; Tekeoğlu İ; Tolu S; Toprak M; Tuncer T
    Joint Bone Spine; 2021 Jul; 88(4):105177. PubMed ID: 33771757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application and modifications of minimal disease activity measures for patients with psoriatic arthritis treated with adalimumab: subanalyses of ADEPT.
    Mease PJ; Heckaman M; Kary S; Kupper H
    J Rheumatol; 2013 May; 40(5):647-52. PubMed ID: 23504383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remission in psoriatic arthritis.
    Gladman DD; Hing EN; Schentag CT; Cook RJ
    J Rheumatol; 2001 May; 28(5):1045-8. PubMed ID: 11361187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical remission in patients with active psoriatic arthritis treated with adalimumab and correlations in joint and skin manifestations.
    Van den Bosch F; Kavanaugh A; Kron M; Kupper H; Mease PJ
    J Rheumatol; 2015 Jun; 42(6):952-9. PubMed ID: 25834212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
    Lubrano E; Parsons WJ; Perrotta FM
    J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin.
    Marin J; Acosta Felquer ML; Ferreyra Garrot L; Ruta S; Rosa J; Soriano ER
    J Rheumatol; 2016 May; 43(5):907-10. PubMed ID: 26932341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
    J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
    Perrotta FM; Marchesoni A; Lubrano E
    J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature.
    Gossec L; McGonagle D; Korotaeva T; Lubrano E; de Miguel E; Østergaard M; Behrens F
    J Rheumatol; 2018 Jan; 45(1):6-13. PubMed ID: 29142032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis.
    Iannone F; Nivuori M; Fornaro M; Venerito V; Cacciapaglia F; Lopalco G
    Rheumatology (Oxford); 2020 Jul; 59(7):1599-1606. PubMed ID: 31652315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.
    Gorlier C; Orbai AM; Puyraimond-Zemmour D; Coates LC; Kiltz U; Leung YY; Palominos P; Cañete JD; Scrivo R; Balanescu A; Dernis E; Tälli S; Ruyssen-Witrand A; Soubrier M; Aydin SZ; Eder L; Gaydukova I; Lubrano E; Kalyoncu U; Richette P; Husni ME; de Wit M; Smolen JS; Gossec L
    Ann Rheum Dis; 2019 Feb; 78(2):201-208. PubMed ID: 30442648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.
    van Mens LJJ; van de Sande MGH; van Kuijk AWR; Baeten D; Coates LC
    Ann Rheum Dis; 2018 Feb; 77(2):251-257. PubMed ID: 29080861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.
    Coates LC; Rahman P; Psaradellis E; Rampakakis E; Osborne B; Lehman AJ; Nantel F
    Rheumatology (Oxford); 2019 Mar; 58(3):522-526. PubMed ID: 30517715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.